Search
for
Sort by
Research 331–360 of 521
- Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease
- Dermatolojik Problemler ve COVID-19
- Maintenance, withdrawal, and re-treatment with ritlecitinib and brepocitinib in patients with alopecia areata in a single-blind extension of a phase 2a randomized clinical trial
- Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A promising therapy for the treatment of alopecia areata: A case report of six patients
- Clinical response to oral tofacitinib in pediatric patients with alopecia areata
- Therapeutic update on alopecia areata: a critical review of standard and emerging targeted therapies
- P88 Real-world evidence on efficacy and safety of Janus Kinase inhibitors in the treatment of moderate to severe active Ulcerative Colitis
- 705 Particulate matter induces inflammatory response in human outer root sheath cells via oxidative stress-dependent MAPK and JAK-STAT signaling pathways
- Interleukin-15 and Tumor Necrosis Factor-α in Iraqi Patients with Alopecia Areata
- Case Report: Successful Treatment of Alopecia Universalis With Tofacitinib and Increased Cytokine Levels: Normal Therapeutic Reaction or Danger Signal?
- Pharmacologic inhibition of JAK-STAT signaling promotes hair growth
- Targeting the Janus Kinase Family in Autoimmune Skin Diseases
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
- New and Emerging Therapies for Alopecia Areata
- A Case of Topical Ruxolitinib Treatment Failure in Alopecia Areata
- JAK inhibition in the treatment of alopecia areata – a promising new dawn?
- Comparative efficacy of oral Janus kinase inhibitors and biologics in adult alopecia areata: A systematic review and Bayesian network meta‐analysis
- Evaluation of the level of serum Interleukins (IL-2, IL-4, IL-15 andIL-17) and its relationship with disease severity in patients with alopecia areata
- Induction of T cell exhaustion by JAK1/3 inhibition in the treatment of alopecia areata
- Efficacy and safety of tofacitinib therapy in Asian patients with severe alopecia areata
- Off-Label Uses of Abrocitinib: Review of Emerging Therapeutic Applications beyond Atopic Dermatitis
- Alopecia Areata: Case report and review of pathophysiology and treatment with Jak inhibitors
- Case report: Psoriasiform eczema with immune-mediated comorbidities treated with upadacitinib
- Interleukin-15 is a hair follicle immune privilege guardian
- Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions
- Use of Jak Inhibitors in the Treatment of Alopecia Areata
- Pharmacological activities of Abrus precatorius Linn.: A comprehensive review of its ethnomedicinal uses and phytochemical profile.
- Pharmacological activities of Abrus precatorius Linn.: A comprehensive review of its ethnomedicinal uses and phytochemical profile.
- Network pharmacology, molecular docking, and dynamics reveal the mechanisms of Hejie Shengfa Decoction against alopecia areata
- Approach to Managing Recalcitrant Alopecia Areata with Combination Therapy: A Series of Five Cases in Black Pediatric Patients